Bio.News reports on NBDF's World Hemophilia Day initiatives, emphasizing equal care for women and girls with bleeding disorders.

Urgent: Federal health programs for bleeding disorders face cuts. Contact your lawmakers to protect CDC funding and vital support.

Major HHS restructuring impacts CDC blood disorder programs. See how NBDF and advocates are responding. Plus state updates.

A newly published journal article examined current practices of HTCs for screening and assessing bone health in people with hemophilia and von Willebrand disease.

We are celebrating this National Social Work Month of March by highlighting resources to help support our hemophilia treatment center social workers and to recognize the critical work they do on behalf of people with bleeding disorders and their families.

Takeda Pharmaceuticals announced today it will globally discontinue two of its hemophilia treatments: HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)].

Included in this edition are educational booklets, articles, and video recordings of substantive presentations on topics related to rare factor deficiencies and inherited platelet disorders.

On Jan 27, 2025, Bill Robie testified before North Dakota lawmakers in support of HB 1216, aiming to lower out-of-pocket drug costs for bleeding disorders.

NBDF reaffirms its dedication to all in the bleeding disorders community, prioritizing health equity, diversity, and inclusion.